Spectral Medical Inc (EDTXF) Stock
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Spectral Medical Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Spectral Medical Inc is headquartered in CA.
Spectral Medical Inc (EDTXF) stock trades at $0.97 with a market capitalization of $284.16M. The stock is valued at a price-to-earnings (P/E) ratio of -9.89, price-to-book of -5.59, price-to-sales of 143.47. Over the past 52 weeks the stock has ranged between $0.58 and $1.31, and currently trades 26.0% below its 52-week high.
On profitability, Spectral Medical Inc generates a return on equity (ROE) of 61.00% — well above the market average, a sign of a high-quality business, return on capital employed of 18.69%, an operating margin of -412.28%, a net profit margin of -2400.00%.
Official website: spectraldx.com